PMS-IPRATROPIUM SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

IPRATROPIUM BROMIDE

Prieinama:

PHARMASCIENCE INC

ATC kodas:

R03BB01

INN (Tarptautinis Pavadinimas):

IPRATROPIUM BROMIDE

Dozė:

21MCG

Vaisto forma:

SOLUTION

Sudėtis:

IPRATROPIUM BROMIDE 21MCG

Vartojimo būdas:

NASAL

Vienetai pakuotėje:

30ML

Recepto tipas:

Prescription

Gydymo sritis:

ANTIMUSCARINICS ANTISPASMODICS

Produkto santrauka:

Active ingredient group (AIG) number: 0115643002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

1999-02-12

Prekės savybės

_ _
_pms-IPRATROPIUM Product Monograph _
_Page 1 of 26_
PRODUCT MONOGRAPH
PR
PMS-IPRATROPIUM
(Ipratropium Bromide Nasal Spray)
0.03% w/v
(21 μg/metered spray)
TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
Date of Revision:
October 26, 2012
Submission Control No: 157146
_ _
_pms-IPRATROPIUM Product Monograph _
_Page 2 of 26_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................4
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
..............................................................................